Immatics N.V. (IMTX) Form 6-K — Jun 1, 2026
Immatics N.V. presented preliminary clinical data from its TCR-T cell therapy trial in melanoma at a medical conference. The data covers a population of 33 patients with various forms of melanoma, including cutaneous and uveal subtypes, who had received multiple prior lines of systemic therapy. The results highlight durable disease stabilization in several patients, with one patient achieving a progression-free survival of 20.6 months and another maintaining stable disease for 17.3 months.
Key figures
- Patient population size
- 33
- Best overall response type
- Stable Disease (SD)
- Max disease stabilization months
- 17.3
- Max progression free survival months
- 20.6
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.